Members are requested to note that the above security will be a part of special pre-open session for IPO and Other category of scrip’s as per SEBI circular no. CIR/MRD/DP/01/2012 & CIR/MRD/DP/02/2012 dated January 20, 2012.
For further information on SPOS, the trading members are requested to refer to the Exchange’s notice no. 20120216-29 on Enabling Special Pre-open Session for IPO’s & Relisted Scrips. For any clarification on SPOS, the trading members may please contact the Helpdesk on 022-6136 3100 / 6136 3171.
|
Name of the Company
|
:
|
Piramal Pharma Limited
|
|
Registered Office
|
:
:
:
:
:
|
Gr. Floor, Piramal Ananta, Agastya Corp. Park, Kamani Junction, LBS Marg, Kurla, Mumbai - 400070,
Tel: +(91-22) 3802-3000/4000
Fax: 91-22-3802-3884
E-mail ID: corporate.secretarial@piramal.com
Website: www.piramal.com
|
|
Company Secretary & Compliance Officer
|
:
:
:
|
Ms. Tanya Sanish
Tel No +91-022 38023000
Email ID: tanya.dcosta@piramal.com
|
|
Securities
|
:
|
119,33,18,500 Equity shares of Rs. 10/- each allotted pursuant to Scheme of Arrangement
|
|
Distinctive numbers
|
:
|
785010001 to 983930413 ;
1004259488 to 1008247749 ;
1150158482 to 1185913506 ;
1185913507 to 2140568306
|
|
Scrip Code
|
:
|
543635
|
|
Group
|
:
|
T
|
|
Market Lot
|
:
|
1
|
|
Face Value & Paid up value
|
:
|
Rs. 10/- each fully paid
|
|
Scrip ID on BOLT System
|
:
|
PPLPHARMA
|
|
Abbreviated name on BOLT
|
:
|
PPLPHARMA
|
|
ISIN No.
|
:
|
INE0DK501011
|
|
Lock-in
|
:
|
Quantity
|
Dist. Nos.
|
Lock in Upto
|
|
:
|
23,86,63,700
|
785010001- 983930413;
1004259488- 1008247749;
1150158482-1185913506
|
19.10.2023
|
1. The brief particulars of the Composite Scheme of Arrangement are as mentioned below:
a) The Composite Scheme of Arrangement of the Company was approved by the Hon'ble National Company Law Tribunal (NCLT) at Mumbai Bench vide its Order dated 12.08.2022.
b) Appointed Date: 01.04.2022
c) Effective date: 18.08.2022
d) Date of Allotment: 05.09.2022
e) Pursuant to the Composite Scheme of Arrangement between Piramal Enterprises Limited (Demerged Company/ Amalgamated FS Company) and Piramal Pharma Limited (Resulting Company/ Amalgamated Pharma Company) and Convergence Chemicals Private Limited (Amalgamating Pharma Company 1) and Hemmo Pharmaceuticals Private Limited (Amalgamating Pharma Company 2) and PHL Fininvest Private Limited (Amalgamating FS Company) and their respective Shareholders and Creditors, sanctioned by the Hon’ble National Company Law Tribunal, Mumbai Bench; whereby upon coming into effect of the scheme and in consideration of:
· Pursuant to Demerger, the transfer of the Pharma Business Undertaking (Demerged Undertaking) of Piramal Enterprises Limited and vesting of the same with and into Piramal Pharma Limited; Piramal Pharma Limited shall issue and allot equity shares credited as fully paid-up to the shareholders of Piramal Enterprises Limited in the following proportion:
· “4 equity shares of Face value of Rs.10/- each fully paid up of Piramal Pharma Limited shall be issued and allotted for every 1 equity share of Face value Rs. 2/- each fully paid up held in Piramal Enterprises Limited”
· Pursuant to Amalgamation of Convergence Chemicals Private Limited and Hemmo Pharmaceuticals Private Limited with Piramal Pharma Limited, the equity shares of Convergence Chemicals Private Limited and Hemmo Pharmaceuticals Private Limited which are held by Piramal Pharma Limited and its nominees, shall stand cancelled and extinguished and no new shares shall be issued or payment made in cash or in kind by Piramal Pharma Limited.
· Pursuant to Amalgamation of PHL Fininvest Private Limited with Piramal Enterprises Limited, equity shares of PHL Fininvest Private Limited which are held by Piramal Enterprises Limited, and its joint shareholders, shall stand cancelled and extinguished and no new shares shall be issued or payment made in cash or in kind by Piramal Enterprises Limited.
Prior to the Scheme, the paid-up Equity Capital of Piramal Pharma Limited was Rs. 11,85,91,35,060/- consisting of 1,18,59,13,506 equity shares of face value of Rs. 10/- each and further 94,72,49,806 equity shares of face value of Rs. 10/- each of Piramal Pharma Limited which are held by Piramal Enterprises Limited shall stand cancelled upon the scheme coming effect.
The issued, subscribed and paid-up Equity Capital of Piramal Pharma Limited post arrangement is Rs. 11,93,31,85,000/- consisting of 1,19,33,18,500 equity shares of face Value of Rs. 10/- each fully paid.
2. As per Exchange Notice No. 20220825-20 dated 25.08.2022, Piramal Enterprises Limited had fixed Record date as 01.09.2022 for giving effect to the Composite Scheme of Arrangement.
3. The Information Memorandum containing all the information about the company can be viewed at https://www.bseindia.com/corporates/soa.aspx
4. The name and address of the registrar and share transfer agent of the company is as
mentioned below:
LINK INTIME INDIA PRIVATE LIMITED
C-101,247 Park, L.B.S. Marg, Vikhroli (West),
Mumbai - 400 083.
Tel: 022-4918-6000
Fax: 022-49186060
Website: www.linkintime.co.in
E-Mail: shweta.poojari@linkinlime.co.in;
rnt.helpdesk@linkintime.co.in
5. The shareholding pattern of the company post Scheme of Arrangement is enclosed as
Annexure-I.
Sd/-
Prasad Bhide
Senior Manager
|